Teva Pharmaceutical Industries has announced a restructuring plan to reduce its cost base, unify its organisation and improve profitability and productivity.

The plan aims to reduce the company’s total cost base from an estimated $16.1bn in 2017 to around $13bn by the end of 2019.

Teva hopes to achieve more than half of this reduction by the end of next year and expects to record a restructuring charge of at least $700m as a result of the plan’s implementation.

“The plan aims to reduce the company’s total cost base from the estimated $16.1bn in 2017 to around $13bn by the end of 2019.”

Further charges are expected following the closure and divestment of manufacturing plants, research and development (R&D) facilities, headquarters and other office locations, which are expected to result in the reduction of 14,000 positions worldwide.

The majority of these reductions are expected to occur next year, and most affected employees will be notified within the next 90 days.

Teva Pharmaceutical Industries president and CEO Kåre Schultz said: “We will execute this plan in a timely and prudent manner, remaining focused on revenue and cash flow generation, in order to make sure Teva is ready to meet all of its financial commitments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Teva will optimise its cost base while ensuring that we protect our revenues and preserve our core capabilities in generics and in select specialty assets, in order to secure long-term growth.”

Teva will work to improve profitability in all existing markets and will carry out a review of all R&D programmes.

Next year, the company expects to secure the launches of Austedo and fremanezumab tablets.